Investment Thesis
Mosaic ImmunoEngineering exhibits severe financial distress with negative stockholders' equity of -$7.3M, liabilities exceeding assets by a substantial margin, and minimal operating capacity. The company is burning cash with negative operating cash flow of -$83.3K, deteriorating liquidity ratios (0.01x current ratio), and lacks meaningful revenue generation, making continued operations unsustainable without significant capital infusion or restructuring.
Strengths
- Minimal capital expenditure requirements suggest low ongoing operational needs
- Small absolute scale of cash burn provides limited time before complete depletion
- Historical data suggests some previous gross profit generation capability
Risks
- Negative stockholders' equity indicating technical insolvency and potential equity wipeout
- Critical liquidity crisis with current ratio of 0.01x and only $31.8K cash against $7.4M liabilities
- Negative operating cash flow combined with revenue N/A indicates non-viable business model
- Net losses continuing to accumulate with persistent operating deficits
- Zero insider activity in last 90 days suggests management disengagement
- Extremely poor asset efficiency with -938% ROA
Key Metrics to Watch
- Stockholders equity trajectory toward reorganization or dissolution
- Cash burn rate and months of cash runway remaining
- Revenue generation attempts and gross margin sustainability
Financial Metrics
Revenue
N/A
Net Income
-518.7K
EPS (Diluted)
$-0.07
Free Cash Flow
-83.3K
Total Assets
55.3K
Cash
31.8K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-938.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.01x
Quick Ratio
0.01x
Debt/Equity
N/A
Debt/Assets
13,313.6%
Interest Coverage
-62.56x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T21:14:10.127929 |
Data as of: 2025-09-30 |
Powered by Claude AI